Sharon Weiner, MD
Critical Care Medicine · Eatontown, NJNPI 1316918618
Payments from drug & device makers
Across 121 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$536
- Boehringer Ingelheim$275
- GSK$251
- AstraZeneca$154
- Mylan Specialty L.p.$127
- Sanofi$124
- plus $680 from 15 others
What the payments were for
- Food & beverage$1,97192%
- Education$1768%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 34 | $536 |
| Boehringer Ingelheim | 14 | $275 |
| GSK | 17 | $251 |
| AstraZeneca | 11 | $154 |
| Mylan Specialty L.p. | 8 | $127 |
| Sanofi | 7 | $124 |
| United Therapeutics Corporation | 7 | $119 |
| Pulmonx Corporation | 1 | $92 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Insmed, Inc. | 3 | $57 |
| Philips North America LLC | 3 | $46 |
| Regeneron Healthcare Solutions, Inc. | 3 | $45 |
| Covidien LP | 1 | $45 |
| Viatris Specialty LLC | 2 | $40 |
| Merck | 2 | $30 |
| Genentech USA, Inc. | 2 | $29 |
| Baxter Healthcare | 1 | $25 |
| Verona Pharma, Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Circassia Inc. | 1 | $13 |
How this compares
$2,146 in reported general payments places this provider in the 75th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 19 | $242,544 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 170 | $163,904 |
| Spiriva RespimatTiotropium Bromide | 34 | $35,536 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $28,465 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $17,194 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $15,833 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $14,027 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $12,355 |
| Arnuity ElliptaFluticasone Furoate | 23 | $8,237 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $7,106 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $6,352 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $4,410 |
| Montelukast Sodium | 203 | $2,336 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $733 |
| Famotidine | 29 | $577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $275 | $290,43569 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $251 | $216,439270 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $154 | $23,54638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Eatontown
- Fariborz RezaiLivingston$2.4M
- Ronak ShahHackensack$439K
- Eric SztejmanMarlton$231K
- Eric TellerHackensack$217K
- Steven ChangNewark$191K
- Jonathan GalliMarlton$128K
- Keith RoseHackensack$112K
- R Phillip DellingerCamden$74K
- Theodore PlushCamden$63K
- Ricardo VerdinerNew Brunswick$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.